Clinical Trial Update: Phase I Study of Anti-CD22 Chimeric Receptor T Cells in Patients With Relapsed/Refractory Hairy Cell Leukemia and Variant [Phase 1]

View source ↗

Summary

Phase I clinical trial evaluating anti-CD22 CAR-T cells in patients with relapsed/refractory hairy cell leukemia and hairy cell leukemia variant; currently recr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hairy Cell Leukemia
• Hairy Cell Leukemia Variant

Drugs mentioned

• Anti-CD22 CAR-T cells

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Hairy Cell Leukemia, Hairy Cell Leukemia Variant | Phase 1 | Status: RECRUITING